To date, a number of therapeutics blocking this pathway have been examined in phase I trials, but only one has been examined in a phase II trial specifically addressing ovarian cancer; the anti-HGF IgG2 humanized antibody, AMG 10243, 44. This evidence concerns the gene HGF and ovarian carcinoma.